ADOCIA Announces The Release of its Universal Registration Document for the Year 2020
April 21 2021 - 1:30AM
Business Wire
Regulatory News:
Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC- the
“Company”), announces the filing of its 2020 Universal Registration
Document (Document d’Enregistrement Universel) with the “Autorité
des marchés financiers” (AMF - the French financial markets
regulator) on April 20th, 2021.
An electronic copy of this document is available on the
company’s website (www.adocia.com) as well as on the website of the
AMF (www.amf-france). Hard copies are available upon request at the
company’s headquarters located 115, avenue Lacassagne, 69003
Lyon.
The universal registration document includes the 2020 Annual
Financial Report, which includes the 2020 Management Report, and
the report on Corporate Governance.
About ADOCIA
Adocia is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic proteins and peptides for the treatment of diabetes and
metabolic diseases. In the diabetes field, Adocia’s portfolio of
injectable treatments is among the largest and most differentiated
of the industry, featuring five clinical-stage products and three
products in preclinical-stage. The proprietary BioChaperone®
technological platform is designed to enhance the effectiveness
and/or safety of therapeutic proteins while making them easier for
patients to use. Adocia customizes BioChaperone to each protein for
a given application.
Adocia’s clinical pipeline includes four novel insulin
formulations for prandial treatment of diabetes: two ultra-rapid
formulations of insulin analog lispro (BioChaperone® Lispro U100
and U200), a combination of basal insulin glargine and rapid-acting
insulin lispro (BioChaperone® Combo) and one combination of a
prandial insulin with amylin analog pramlintide M1Pram. The
clinical pipeline also includes an aqueous formulation of human
glucagon (BioChaperone® Glucagon) for the treatment of
hypoglycemia.
Adocia preclinical pipeline includes three bi-hormonal products:
two combinations of rapid human insulin analogues and Pramlintide
(BioChaperone® LisPram and BioChaperone® AsPram) and a combination
of insulin glargine with Liraglutide (BioChaperone® GlaLira) for
the treatment of diabetes and a combination of glucagon and GLP-1
receptor agonist (BioChaperone® Glucagon GLP-1 ) for the treatment
of obesity. Adocia recently added a fourth program in preclinical
with the development of a hydrogel scaffold for cell therapy in the
treatment of type 1 diabetes. A first patent has been filed.
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
“Risk Factors” section of the Universal Registration Document filed
with the French Autorité des marchés financiers on April 20, 2021
(a copy of which is available at www.adocia.com ) and to the
development of economic conditions financial markets and the
markets in which Adocia operates. The forward-looking statements
contained in this press release are also subject to risks not yet
known to Adocia or not currently considered material by Adocia. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance, or achievements of Adocia to be
materially different from such forward-looking statements. This
press release and the information contained herein do not
constitute an offer to sell or the solicitation of an offer to buy
Adocia shares in any jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210420006081/en/
Adocia Gérard Soula CEO
contactinvestisseurs@adocia.com Ph: +33 4 72 610 610 www.adocia.com
MC Services AG Adocia Press Relations Europe
Raimund Gabriel Managing Partner adocia@mc-services.eu Ph:
+49 89 210 228 0 The Ruth Group Adocia Investor Relations
USA James Salierno Vice-President
jsalierno@theruthgroup.com Ph.: +1 646 536 7035
Adocia (EU:ADOC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adocia (EU:ADOC)
Historical Stock Chart
From Apr 2023 to Apr 2024